Betaxolol Market - Size, Share, Growth, Outlook, and Trends Analysis 2018–2026

Betaxolol is a racemic mixture and beta-adrenergic receptor inhibitor used to treat patients with chronic open-angle glaucoma or ocular hypertension. It was first approved by the U.S. Food and Drug Administration (FDA) in 1989, as an oral tablet. Betaxolol is used either alone or in combination with other medicines to lower down the pressure within the heart or eye. In the heart, Betaxolol decreases the cardiac contractility and rate selectively by actively binding and blocking beta-1 adrenergic receptors. This leads to reduction in cardiac output and lowers blood pressure. Topical applications in the eye reduces aqueous humor secretion and lowers the Intraocular Pressure (IOP) resulting in low risk of optic nerve damage and loss of vision in patients. Betaxolol further inhibits the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels.

Browse Full Report: https://www.coherentmarketinsights.com/ongoing-insight/betaxolol-market-1781

Betaxolol Market Drivers

Increasing prevalence of glaucoma worldwide is propelling growth of the market. According to the Glaucoma research Foundation, glaucoma is the leading cause of irreversible blindness worldwide. Around 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be suffering from glaucoma worldwide, in 2013. Furthermore, according to the American Academy of Ophthalmology, the prevalence of glaucoma is high in Africa and Latin America. Patients who fail to respond to medications, undergo trabeculectomy surgery. - 50 patients per million of the population. Although treatment available for pulmonary arterial hypertension is limited, beta-adrenergic receptor inhibitor, Prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors are available to decrease symptoms, slow down disease progression, and improve the quality of life.

Betaxolol Market Restraint

Stringent regulatory approvals to ensure the safety of drugs and patent expiry of betaxolol drugs such as Betoptic S and Betoptic Liq, are major challenge for growth of the market, as the generic versions of these drugs are sold at 70% to 80% lower prices as compared to the branded drugs.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1781

Betaxolol Market - Regional Analysis

Geographically, global betaxolol market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the maximum share for ocular surgery, owing to high prevalence of diabetes and eye related disorders among the populace in the region. According to National Federation of the blind, 2014, around 1.3 million people were legally blind in the U.S. and estimated that over 75,000 people in the U.S. are expected to suffer from blindness or visual impairment annually. Furthermore, Asia Pacific betaxolol market is expected to witness significant growth owing to the presence of generic key players such as Lupin Ltd. And Cipla Ltd. especially in India, which are engaged in manufacturing the generics of betaxolol to retain the market share in the region.

The market players operating in betaxolol market include Novartis AG, Genix Pharma (Pvt.) Ltd., East West Pharma, Hetero Healthcare Ltd. (GenX), Cadila Pharmaceuticals Ltd., Jawa Pharmaceuticals (INDIA) Pvt. Ltd., DAL Medical Services Company Ltd, Sentiss Pharma Pvt. Ltd., Humanwell Healthcare Group, and PuraCap Pharmaceutical LLC.

Request TOC of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1781

Betaxolol Market Taxonomy

By Dosage Form: Tablets, Suspension,.

By Disease Indication: Glaucoma, Ocular Hypertension,.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies,.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.